Hydrogel

Kirigami hydrogels rise from cellulose film

Retrieved on: 
Friday, April 12, 2024
Science, Nanofiber, Gel, University of Tokyo, Swelling, Administration, Hydrogel, Research, Kirigami, Water, The Journal, Cellulose, Tissue engineering, Movement, Growth, Advanced Materials

Their work extends the emerging field of 'kirigami hydrogels', in which patterns are cut into a thin film allowing it to later swell into complex hydrogel structures.

Key Points: 
  • Their work extends the emerging field of 'kirigami hydrogels', in which patterns are cut into a thin film allowing it to later swell into complex hydrogel structures.
  • Researchers Daisuke Nakagawa and Itsuo Hanasaki worked with an initially dry film composed of nanofibers of cellulose, the natural material that forms much of the structure of plant cell walls.
  • They used laser processing to cut structures into the film before water was added allowing the film to swell.
  • The advance in kirigami hydrogels achieved by the TUAT team significantly extends the options for future hydrogel applications.

Innosphere Ventures Fund Announces Major Investment in GelSana to Revolutionize Advanced Wound Care

Retrieved on: 
Thursday, November 30, 2023
FDA, Cardinal Health, CO, Hydrogel, IP, Fort Collins, Colorado

Fort Collins, CO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures Fund is thrilled to announce a significant follow-on investment in GelSana, a groundbreaking company in the advanced wound care industry.

Key Points: 
  • Fort Collins, CO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures Fund is thrilled to announce a significant follow-on investment in GelSana, a groundbreaking company in the advanced wound care industry.
  • In this funding round, Innosphere Ventures Fund led the way as the lead investor, with Mines Venture Fund also participating significantly.
  • This investment marks a pivotal moment in GelSana's journey to disrupt the advanced wound care market, which currently consists of competitors such as 3M, Smith+Nephew, Coloplast, and Cardinal Health.
  • Additionally, GelSana's elastic hydrogels have the unique ability to stretch and self-heal, making them ideal for various wound care applications.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, November 15, 2023
CNS, Sale, CSMC, Retina, Patient, Triple-negative breast cancer, Attention deficit hyperactivity disorder, Cayman, Investigational New Drug, US FDA, Licensed production, Cancer, Power purchase agreement, SIV, Security (finance), Toxicity, Plasma protein binding, Syndrome, IND, Surgeon, TGA, BioLite, ADHD, Taiwan Stock Exchange, Sales management, Hydrogel, MDD, Pancreatic cancer, Depression, GMP, Good manufacturing practice, Bank statement, UCSF, MDS, University, Partnership, Phase, Drug development, Research, ANDA, Warrant, FDA, Dietary supplement, West Pharmaceutical Services, Share (finance), Pharmaceutical industry, Cryptocurrency, Qiu Zhonghui

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel

Retrieved on: 
Tuesday, December 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Clinical Trials, Harvard University, Safety, Simon Business School, University of Zurich, Senior, Erythema, INN, EIC, Patient, University of Rochester, Regenerative medicine, Medical Affairs Bureau, Wound healing, MBA, Bleeding, University, Phase, Debridement, Growth, Medicine, Doctor of Philosophy, Edema, Hydrogel, Pharmaceutical industry, Nursing, Boston, Dermatology

The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).

Key Points: 
  • The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).
  • SolasCure’s CLEANVLU Phase IIa clinical trial observed a strong safety profile for Aurase Wound Gel, with no evidence of systemic availability, no antibody generation to the enzyme and no effects on systemic coagulation pathways.
  • SolasCure’s Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing.
  • Aurase Wound Gel is due to enter further Phase II trials to further evaluate its efficacy across a larger and more diverse patient group than the Phase IIa study, with the positive safety data obtained from the Phase IIa trial allowing for higher concentrations of the gel to now be explored.

Rising Demand for Hydrogel-Based Medical Implants Propels Market Growth, Unveils Comprehensive Report on Hydrogel Technologies - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 2, 2023
Chemicals, Plastics, Medical Devices, Health, Manufacturing, Other Health, General Health, Water purification, Electronics, Hydrogel, Fertilizer, Energy applications of nanotechnology, Membrane, Filtration, Livestock, Bioreactor, Magnetism, Tissue engineering, Cosmetics, Gel, SWOT, Adsorption, Highlight, Soil, Flexible electronics, Agriculture, Boston Scientific, SWOT analysis, Electrolyte, Electrode, Sewage treatment, Medical device

Healthcare Applications: The study analyzes the diverse uses of hydrogels in healthcare, such as wound care, drug delivery, medical implants, tissue engineering, cosmetics, and biosensors.

Key Points: 
  • Healthcare Applications: The study analyzes the diverse uses of hydrogels in healthcare, such as wound care, drug delivery, medical implants, tissue engineering, cosmetics, and biosensors.
  • Water Purification Methods: Detailed exploration of water purification methods involving hydrogels, including adsorption, solar evaporation, filtration, and magnetics.
  • Flexible Electronics Uses: The report explores hydrogel uses in flexible electronics, such as batteries, supercapacitors, printed circuits, and transistors.
  • Profiles of Leading Companies: The report profiles over 70 leading companies at the forefront of hydrogel technologies and products.

L2P Research Labs Awarded NIH SBIR Grant for Arthritis, Musculoskeletal and Skin Diseases Research

Retrieved on: 
Friday, October 27, 2023
Pharmaceutical, Science, Health, Research, Stem cell, Labs, MSC, Pain management, Pain, ASC, Motion, Hydrogel, Arthroplasty, B cell, Medical imaging, Osteoarthritis

No treatments other than arthroplasty have been developed to stop its progression, reduce pain, and increase range of motion.

Key Points: 
  • No treatments other than arthroplasty have been developed to stop its progression, reduce pain, and increase range of motion.
  • L2P Labs will aim to combine the use of hydrogel, stem cells, and ultrasound therapy to develop a new treatment for osteoarthritis.
  • Dr. Suresh Anaganti, Chief Executive Officer of L2P Research, added “This research will address a huge unmet need for disease modification (compared to mere pain management) in the osteoarthritis field.
  • Importantly, these experiments have been designed to facilitate a rapid proof-of-concept to pave the way for future clinical studies.”

Electronics Industry Leverages Hydrogel Innovations to Address Market Drivers for Flexible and Efficient Electronics Components

Retrieved on: 
Friday, November 3, 2023
Water purification, Electronics, Hydrogel, Fertilizer, Energy applications of nanotechnology, Membrane, Filtration, Livestock, Bioreactor, Magnetism, Tissue engineering, Cosmetics, Gel, SWOT, Adsorption, Highlight, Soil, Flexible electronics, Agriculture, Boston Scientific, SWOT analysis, Electrolyte, Electrode, Sewage treatment, Medical device

Water Purification Methods: Detailed exploration of water purification methods involving hydrogels, including adsorption, solar evaporation, filtration, and magnetics.

Key Points: 
  • Water Purification Methods: Detailed exploration of water purification methods involving hydrogels, including adsorption, solar evaporation, filtration, and magnetics.
  • Flexible Electronics Uses: The report explores hydrogel uses in flexible electronics, such as batteries, supercapacitors, printed circuits, and transistors.
  • Energy Applications: Insights into hydrogel applications in energy, including battery electrodes & electrolytes, fuel cell membranes, and solar cells.
  • Growth Drivers and Challenges: Detailed insights into the growth drivers, trends, and challenges in key hydrogel application areas.

NUS scientists develop innovative magnetic gel that heals diabetic wounds three times faster

Retrieved on: 
Thursday, October 19, 2023
Wuhan University of Technology, FDA, Engineering, NUS, Connective tissue, Yale-NUS College, Burns, Patent, Hydrogel, Keratinocyte, Orthopedic surgery, National University of Singapore, Agency, Sun, Diabetes, Infection, Nanyang Technological University, Wallace H. Coulter Department of Biomedical Engineering, Sengkang General Hospital, Cell, Fibroblast, Multimedia, Collagen, Quality of life, Tissue, Regeneration, Advanced Materials, Recurrence, Walking, National university, Agency for Science, Technology and Research, Blood, Overalls, Ulcer, Wound healing, Amputation, Patient, Biomedicine, Communication, Consultant, Biomedical engineering, Medical imaging, Electric motor, Nursing, Pharmaceutical industry, Dentistry, Research, Science

SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- Diabetic patients, whose natural wound-healing capabilities are compromised, often develop chronic wounds that are slow to heal. Such non-healing wounds could cause serious infections resulting in painful outcomes such as limb amputation. To address this global healthcare challenge, a team of researchers from the National University of Singapore (NUS) engineered an innovative magnetic wound-healing gel that promises to accelerate the healing of diabetic wounds, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.

Key Points: 
  • Lab tests showed the treatment coupled with magnetic stimulation healed diabetic wounds about three times faster than current conventional approaches.
  • Furthermore, while the research has focussed on healing diabetic foot ulcers, the technology has potential for treating a wide range of complex wounds such as burns.
  • Chronic diabetic wounds such as foot ulcers (one of the most common and hardest to treat wounds) have therefore become a major global healthcare challenge.
  • While the magnetic wound-healing gel has shown great promise in improving diabetic wound healing, it could also revolutionise the treatment of other complex wound types.

Cell Reports Medicine Publication Demonstrates How Gelesis’ Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Diabetes, Fitness & Nutrition, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Paper, Sugar, Multimedia, Gel, DSM-IV codes, OSH, Doctor of Philosophy, Obesity, Hydrogel, Prevalence, Weight loss, Gelesis, Diet-induced obesity model, Metabolic syndrome, Humanitas University, Inulin, NASH, Psyllium, Liver disease, Fatty liver disease, Growth, NAFLD, Dietary supplement, Akkermansia

The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH.

Key Points: 
  • The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH.
  • The Gelesis OSH consistently resulted in weight loss, improved insulin sensitivity, and prevented the progression of NAFLD.
  • The study also demonstrated that the beneficial metabolic effects were independent of the weight loss effect.
  • “Our work shows the potential of oral superabsorbent hydrogels to be an effective and non-invasive therapeutic tool in the long-term treatment of obesity and metabolic disorders.”

The FDA Approves IDE for ReGelTec’s Pivotal Study of HYDRAFIL® for Chronic Low Back Pain due to Degenerative Disc Disease

Retrieved on: 
Thursday, September 28, 2023
FDA, Health, Surgery, Medical Devices, Low back pain, Degenerative disc disease, VAPO, Hydrogel, Comprehensive, Oswestry Disability Index, Patient, Clinical research, IDE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Pharmaceutical industry, Vapotherm

ReGelTec, Inc. , announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System.

Key Points: 
  • ReGelTec, Inc. , announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System.
  • The HYDRAFIL System contains an injectable polymer that is implanted percutaneously via a needle to augment the native disc in a procedure performed under local anesthesia at an outpatient surgery center.
  • The HYDRogel Augmentation For Intervertebral Lumbar Discs (HYDRAFIL-D) Study , is a multicenter, single-blinded, randomized, controlled trial to evaluate the safety and efficacy of the HYDRAFIL System for treatment of chronic low back pain due to degenerative disc disease.
  • The HYDRAFIL-D Study will enroll approximately 225 patients in up to fifteen centers across North America and is expected to start in early 2024 after the company completes its next round of financing.